Skip to main content

Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · Delayed Price · USD
71.17
-0.44 (-0.61%)
Pre-market:Sep 20, 2021 7:25 AM EDT
71.61
0.28 (0.39%)
At close: Sep 17, 4:00 PM
Market Cap89.79B
Revenue (ttm)26.64B
Net Income (ttm)5.16B
Shares Out1.26B
EPS (ttm)4.09
PE Ratio17.53
Forward PE10.66
Dividend$2.78 (3.88%)
Ex-Dividend DateSep 14, 2021
Volume5,352,772
Open70.86
Previous Close71.33
Day's Range70.44 - 71.76
52-Week Range54.64 - 72.61
Beta0.41
AnalystsBuy
Price Target75.99 (+6.1%)
Est. Earnings DateOct 27, 2021

About GILD

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of l...

IndustryBiotechnology
IPO DateJan 22, 1992
CEODaniel O'Day
Employees13,600
Stock ExchangeNASDAQ
Ticker SymbolGILD
Full Company Profile

Financial Performance

In 2020, GILD's revenue was $24.69 billion, an increase of 9.98% compared to the previous year's $22.45 billion. Earnings were $123.00 million, a decrease of -97.72%.

Financial Statements

Analyst Forecast

According to 32 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is 75.99, which is an increase of 6.12% from the latest price.

Price Target
$75.99
(6.12% upside)
Analyst Consensus: Buy

News

Gilead Churns Out Additional Trodelvy Data

Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who...

3 days ago - Benzinga

Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cance...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed or r...

4 days ago - Business Wire

New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of In...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in patients with relap...

4 days ago - Business Wire

Gilead Sciences (GILD) Stock Moves 0.23%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $71.15, marking a +0.23% move from the previous day.

6 days ago - Zacks Investment Research

Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new research on its first-in-class antibody-drug conjugate (ADC) Trodelvy® (sacituzumab gov...

6 days ago - Business Wire

This Cancer Screening Company Has A Better 5-Year Return Than Pfizer, Johnson & Johnson And Gilead

Small-cap stocks have a history of outperforming large-cap names as they have the potential for rapid growth and have event-driven moves for share prices. A company focused on cancer screening and diagn...

Other symbols:JNJPFE
1 week ago - Benzinga

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $72.34, moving +0.65% from the previous trading session.

2 weeks ago - Zacks Investment Research

Apple Ranked Among September's Top Buys As Investors Dive Into Fall

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. This month, our deep-learning algorithms have identified Apple among others.

Other symbols:AAPLFIVEGDMU
2 weeks ago - Forbes

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)---- $GILD #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: Morgan Stanley Annua...

2 weeks ago - Business Wire

COVID 19 Stocks -- Vaccines, Diagnostics, or Treatments?

Which subset of the COVID-19 healthcare market will outperform over the next year?

Other symbols:CDNANVAX
2 weeks ago - The Motley Fool

Could Moderna Take Down Gilead Sciences?

It's too early for a "yes" answer. But it's too premature for a "no" response as well.

Other symbols:MRNA
3 weeks ago - The Motley Fool

Gilead Wins Reversal of $1.2B Patent Loss to Bristol-Myers: Bloomberg

Gilead Sciences Inc (NASDAQ: GILD) persuaded a U.S. appeals court to reverse a $1.2 billion judgment Bristol-Myers Squibb & Co (NYSE: BMY) had won over immuno-oncology treatments. The patent owned by Br...

3 weeks ago - Benzinga

Gilead Sciences wins reversal of $1.2 billion fine against Bristol Myers in patent case

U.S. biotech Gilead Sciences Inc escaped a $1.2 billion penalty after a U.S. appeals court on Thursday found that relevant parts of a patent on a cancer therapy owned by a Bristol Myers Squibb unit that...

Other symbols:BMY
3 weeks ago - Reuters

Gilead (GILD) MAA for HIV Inhibitor Under the EMA's Review

Gilead's (GILD) application for an investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, is under review with the European regulatory body.

4 weeks ago - Zacks Investment Research

European Medicines Agency Validates Gilead's Marketing Authorization Application for Lenacapavir, an Investigational,...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Marketing Authorization Application (MAA) for lenacapavir, an investigational, long-acting H...

1 month ago - Business Wire

Rand Paul's wife bought Gilead shares in early days of Covid, the couple's only individual stock purchase in years

GOP Sen. Rand Paul and his wife had not bought stock in an individual company in at least 10 years before Kelley Paul purchased Gilead shares in early 2020.

1 month ago - CNBC

How Are Biotech ETFs Reacting to These Q2 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Other symbols:AMGNBBHBIIBIBBXBI
1 month ago - Zacks Investment Research

Fake Versions Of Gilead's HIV Drugs Are In Circulation In US

Gilead Sciences Inc (NASDAQ: GILD) warned Thursday that its original HIV treatments Biktarvy and Descovy had been replaced by fake versions at some pharmacies. Unauthorized distributors could sell fake ...

1 month ago - Benzinga

FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues

FATE reports a wider loss on increased R&D expenses in the second quarter.

Other symbols:BMYFATEJNJ
1 month ago - Zacks Investment Research

Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer

SANTA MONICA, Calif. & LOS ANGELES--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from...

1 month ago - Business Wire

3 Biotech Stocks That Could Make You Richer in August (and Beyond)

All three have blockbuster products already on the market.

Other symbols:MRNAREGN
1 month ago - The Motley Fool

7 Stocks to Buy for Responsibility and Sustainability

With social responsibility taking a greater role in politics and Wall Street, these ESG stocks may find favor in your portfolio. The post 7 Stocks to Buy for Responsibility and Sustainability appeared f...

Other symbols:CLHCPBGOOGHDUL
1 month ago - InvestorPlace

This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money

An effective oral antiviral therapy for the coronavirus may be around the corner.

Other symbols:AVIRMRK
1 month ago - The Motley Fool

BioNTech Completes Acquisition of Kite's Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaith...

MAINZ, Germany & SANTA MONICA, Calif.--(BUSINESS WIRE)--BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing of the acquisition of the sol...

Other symbols:BNTX
1 month ago - Business Wire

5 High-Yield Dividend Stocks for Healthy Income

The healthcare sector is chock-full of safe, sturdy income plays. But these five top-rated high-yield dividend stocks really stand out in the crowd.

Other symbols:ABBVGSKPFEWBA
1 month ago - Kiplinger